Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAK-418 Brain Enzyme Occupancy Study
NCT04202497Phase 1Terminated
- Sponsor
- Takeda
- Start
- Dec 2019
- Primary completion
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of TAK-418 in Kabuki syndrome, sponsored by Takeda. Primary endpoints: Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models At Baseline Scan, Quantitative Estimates of Binding of [18F]MNI-1054 Based on PET Radiotracer Kinetic Models Post-dose at Day 2 and 3 more. Started Dec 2019; status: terminated.
02
Drugs
TAK-418
03
Conditions
Kabuki syndrome
Beyond the preview
Go deeper on NCT04202497.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04202497.